Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report

  • ID: 2227998
  • Report
  • Region: Global
  • 295 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Bayer AG (Germany)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • MORE
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Next Generation Sequencers in US$ Thousand. The Global market is additionally analyzed by the following End-Use Segments: Pharmaceutical/Biotech, Industrial, and Government/Academia.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 93 companies including many key and niche players such as:
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company
  • Fluidigm Corporation
  • Genomatix GmbH
  • Illumina, Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG (Germany)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • MORE

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
Market Outlook
Table 1: Number of AHF Events in the US and EU by Type: 2017E (includes corresponding Graph/Chart)
Sizing the AHF Market
Acute Heart Failure
An Overview of the Disease and Available Therapeutics
Diuretics and Vasodilators
The First Line Therapy for AHF
Other Known Drugs for AHF
Lower Efficacy Thwarts Use

2. MARKET DRIVERS, TRENDS & ISSUES
Conventional Therapies Leave Considerable Unmet Needs
Novel Treatments Offer a Ray of Hope
Key AHF Therapeutics in the Pipeline
Serelaxin Nears Trial Readout form RELAX-AHF-2
Ularitide
A Novel Drug in Development for AHF
The Litany of Drug Failures Expands, Emphasis on Prevention Grows
Other Promising Drugs under Development
Research Findings
Kidney Dysfunction
Predictor of Acute Heart failure
Genetic Influence on Heart Disease among African Americans
Higher Body Mass Index
A Key Risk Factor for AHF
Supplemental Oxygen Therapy May not be for All Cases of AHF
Macro Growth Drivers
Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
Table 2: Economic Burden of Cardiovascular Diseases between 2011 and 2025: Breakdown of Lost Output Value by Income Group (includes corresponding Graph/Chart)
Table 3: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
Table 4: Fatalities by Heart Conditions
Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
Table 5: Fatalities in Low Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
Table 6: Fatalities in Mid Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)
Table 7: Fatalities in High Income Countries by Health Disorder (2015 & 2030): Projected Percentage Breakdown of Number of Deaths for CVD, Cancer, Injury, and Others (includes corresponding Graph/Chart)
CVD: Fast Facts
Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics
Table 8: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
Table 9: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
Table 10: Life Expectancy at Birth in Years of People in Select Countries (2015E) (includes corresponding Graph/Chart)
Table 11: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

3. TREATMENT OF ACUTE HEART FAILURE (AHF)

4. ACUTE HEART FAILURE
THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS
Types of AHF
Causes of AHF
Coronary Heart Disease
Cardiomyopathy
High BP
Damaged Heart Valves
Patho-Physiology of AHF
Signs and Symptoms
Low Output
Fluid Overload/Congestion
Left-Sided Failure
Right-Sided Failure
Biventricular Failure
Diagnosis
Classification of AHF
Left Side and Right Side
Systolic Dysfunction and Diastolic Dysfunction
Backward and Forward Failure
Low-Output Heart Failure and High-Output Heart Failure
Functional Classification
Phases of Evaluation and Management of AHF Patients
Early/Initial Phase
In-Hospital Phase
Pre-Discharge Phase
Early Post-Discharge Phase

5. RECENT INDUSTRY ACTIVITY
Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic
Renova Acquires Stresscopin from Janssen
Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma
CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime
ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug
Trevena’s TRV027 Fails to Meet Clinical Study Endpoints
NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras®
Cardiorentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF
FDA Grants Fast Track Designation to Cardiorentis’ Ularitide
Bristol-Myers Squibb Completes Acquisition of Cardioxyl
Cardiorentis Completes Enrollment in Phase III Trial of Ularitide
Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide
Cardiorentis Enters into Collaboration with Roche
Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic
Cardiorentis Enters into €45 million Financing Agreement with HC Royalty
USPTO Grants Patent to Trevena’s TRV027
FDA Declines Approval for Novartis’ Serelaxin

6. FOCUS ON SELECT PLAYERS
Bayer AG (Germany)
Bristol-Myers Squibb Company (USA)
Cardiorentis AG (Switzerland)
CVie Therapeutics Limited (Taiwan)
Cytokinetics, Inc. (USA)
Merck & Co. (USA)
Novartis AG (Switzerland)
Orion Corporation (Finland)
PhaseBio Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE
Table 12: World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region
US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 13: World 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region
Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
Market Outlook
High AHF Prevalence Drives Demand for Therapeutics
Rising Elderly Population: Key Growth Driver
Table 14: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 15: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 16: US Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

2. JAPAN
A.Market Analysis
Outlook
Aging Population Drive Steady Market Growth
Table 17: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
A Review of Heart Failure Epidemiology in Japan
Japan-Exclusive Drugs Maintain the Lead
Regulatory Overview
B.Market Analytics
Table 18: Japanese Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3. EUROPE
A.Market Analysis
Outlook
Changing Demographics to Propel Market Growth
Table 19: European Population By Age Group (2013, 2020 & 2040): Percentage Share Breakdown of Age Groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart)
ESC Guidelines: Challenges of HFpEF Diagnosis
New EU Guidelines Provides Specifics of Focus for Clinical Trials
B.Market Analytics
Table 20: European Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region
France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 21: European 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of European Markets for Years 2016 and 2022 (includes corresponding Graph/Chart)

3a. FRANCE
Market Analysis
Table 22: French Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3b. GERMANY
A.Market Analysis
Outlook
Bayer AG: Key Germany-based Global Player
B.Market Analytics
Table 23: German Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3c. ITALY
Market Analysis
Table 24: Italian Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM
A.Market Analysis
Outlook
High Levels of Awareness among the Aging Population Drives Market Growth
Table 25: Aging Population in the United Kingdom (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
B.Market Analytics
Table 26: The UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3e. SPAIN
Market Analysis
Table 27: Spanish Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

3f. REST OF EUROPE
A.Market Analysis
Outlook
Heart Failure Statistics Improving in Scotland
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 28: Rest of European Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

4. REST OF WORLD
A.Market Analysis
Outlook
India & China: Potential Laden Markets Offer Lucrative Opportunities
Table 29: Ten Largest Populated Countries Worldwide (July 2015): Total Population (in Millions) by Age Group 0-14 Years, 15-59 Years, 60+ Years for China, India, USA, Indonesia, Brazil, Pakistan, Nigeria, Bangladesh, Russia and Mexico (includes corresponding Graph/Chart)
Table 30: Aging Population in China (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Table 31: Aging Population in India (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Strategic Corporate Developments
CVie Therapeutics Limited
A Taiwan-based Developer of AHF Therapy
B.Market Analytics
Table 32: Rest of World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics Market Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 34 (including Divisions/Subsidiaries 35)

  • The United States (18)
  • Japan (2)
  • Europe (10)
    • Germany (2)
    • The United Kingdom (2)
    • Italy (1)
    • Rest of Europe (5)
  • Asia-Pacific (Excluding Japan) (5)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Cardiorentis AG (Switzerland)
  • CVie Therapeutics Limited (Taiwan)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • Orion Corporation (Finland)
  • PhaseBio Pharmaceuticals, Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll